A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals

AIDS

Volumn 12, Issue 3, 1998, Pages 269-277

  Brosgart, Carol L ^a,l   Louis, Thomas A ^b   Hillman, David W ^c   Craig, Charles P ^d   Alston, Beverly ^e   Fisher, Evelyn ^f   Abrams, Donald I ^a   Luskin Hawk, Roberta L ^g   Sampson, James H ^h   Ward, Douglas J ⁱ   Thompson, Melanie A ^j   Torres, Ramon A ^k  

^a Community Consortium ^*  (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MAYO CLINIC   (United States)

^d ST JOSEPH MERCY HOSPITAL   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f Richmond AIDS Consortium   (United States)

^g AIDS Research Alliance   (United States)

^h Research and Education Group   (United States)

ⁱ Washington Regional AIDS Program   (United States)

^j AIDS Research Consortium of Atlanta   (United States)

^k Clinical Directors Network   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

AIDS; Cytomegalovirus; Disease progression; Herpesvirus; Opportunistic infections; Oral ganciclovir; Prophylaxis; Survival

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; GANCICLOVIR;

ANEMIA; ARTICLE; ASTHENIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; GANCICLOVIR; HUMANS; MALE; TREATMENT OUTCOME;

EID: 6844265589     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199803000-00004     Document Type: Article

References (30)

1. Jacobson MA, Mills J: Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med 1988, 108:585-594.
2. Hoover DR, Saah AJ, Bacellar H, et al.: Clinical manifestations of AIDS in the era of Pneumocytis prophylaxis. N Engl J Med 1993, 329:1922-1926.
3. Chan ISL, Neaton JD, Saravolatz LD, Crane LR, Osterberger J: Frequencies of opportunistic diseases prior to death. AIDS 1995, 9:1145-1151.
4. McKenzie R, Travis WD, Dolan SA, et al.: The causes of death in patients with human immunodeficiency virus infection: a clinical and pathologic study with emphasis on the role of pulmonary diseases. Medicine 1991, 70:326-343.
5. Reichert CM, O'Leary IJ, Levens DL, Simrell CR, Macher AM: Autopsy pathology in the acquired immune deficiency syndrome. Am J Pathol 1983, 112:357-382.
6. Jads DA, Green WR, Fox R, Polk BL, Bartlett JG: Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology 1989, 96:1092-1099.
7. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RL, Zidovudine Epidemiology Study Group: Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992, 166:1223-1227.
8. Pertel P, Hirschtich R, Phair J, et al.: Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992, 5:1069-1074.
9. Hanson DL, Chu SY, Larizo KM, Ward JW, Adult and Adolescent Spectrum of HIV Disease Project Group: Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. Arch Intern Med 1995, 155:1537-1542.
10. Spector SA, McKinley DE, Lalezari et al.: Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996, 334:1491-1497.
11. Deyton L, Carlyn M, Hedderman M, Maiatico G, Hoth D, Fauci A: A national community-based AIDS research program: the Community Programs for Clinical Research on AIDS (CPCRA). VII International Conference on AIDS. Florence, June 1991 [abstract WB2448].
12. Green LA, Neaton JD, Bartsch G, et al.: A clinical event system with committee review for a large clinical trials network [abstract]. Control Clin Trials 1994, 16 (suppl 3):45A.
13. SAS Institute: SAS Version 6.10. Cary: SAS Institute, Inc.; 1996.
14. Mantel N, Raenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
15. Heiss JL: the Design and Analysis of Clinical Experiments. New York: John Wiley and Sons; 1986.
16. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
17. Cox DR: Regression models and life-tables. J R Stat Soc JBJ 1972, 34:187-220.
18. Lan KKG, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 1983, 70:659-663.
19. Il-Sadr W, Oleske JM, Agins BD, et al.: Evaluation and management of early HIV Infection. Clinical Practice Guideline No. 7. [AHCPR Publication No. 94 0572.] Rockville: Agency for Health Care Policy and Research, Public Health Service, US Department o of Health and Human Services; January 1994.
20. Youle MS, Gazzard BG, Johnson MA, et al.: Effects of high-dose acyclovir on herpes virus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. AIDS 1994, 8:641-649.
21. Pertel P, Hirschtick R, Phair J, Chemiel J, Poggensee L, Murphy R: Risk of developing cytomegatovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992, 11:1069-1071.
22. Gonozol E, Plotkin SA: Effect of DNA polymerase inhibitors on the replication of human cytomegalovirus. Arch Virology 1985, 84:129-134.
23. Abrams DL, Goldman AJ, Launer C, et al.: A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994, 330:657-662.
24. 3. 35th Interscience Conference on Antimicrobial Agent and Chemotheraphy. San Francisco, September 1994 [abstract IB-1].
25. Kahn JO, Lagakos SW, Richman DD, et al.: A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992, 327:581-587.
26. Spruance SL, Pavia AL, Peterson D, et al.: Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. Ann Intern Med 1994, 120:360-368.
27. Dolin R, Amato DA, Fischl MA, et al.: Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. Arch Intern Med 1995, 155:961-974.
28. 3. Ann Intern Med 1995, 123:561-571.
29. Yeni P: Preliminary results of the Delta Trial. Presented at the Lifth European Conference on Clinical Aspects and Treatment of HIV. Copenhagen, September 1995.
30. Church L, Dehlinger M, Saravolatz L, et al.: Design of a randomized trial of combined nucleoside analog antiretroviral therapy in AIDS patients. [abstract]. Control Clin Trials 1993, 14:P63.